A translational interaction study found several epidemiological signals but mechanistic support differed across the pairs.
Healthcare-record screening identified an association between alprazolam-loratadine co-exposure and myopathy, among several candidate drug interactions. Laboratory assays suggested that the tested signals were unlikely to result from the evaluated enzyme-inhibition or hepatic-uptake pathways.
The study’s evidence for synergistic cellular myotoxicity concerned simvastatin and desloratadine. That experiment should not be reassigned to the alprazolam-loratadine pair simply because both appeared in the same article.
The observational analysis was vulnerable to residual confounding and exposure or outcome misclassification. A mechanistic assay can exclude or support particular pathways without proving the cause of a clinical association.
For a case assessment, identify the exact interacting pair, muscle findings, timing, and competing causes. This paper supports further investigation of a possible interaction signal, while it does not establish that a specific patient’s muscle injury resulted from alprazolam plus loratadine.
Original analysis of the supplied journal article, identified as PMC4664558.